Aclaris Therapeutics to Participate in Two March Healthcare Conferences

WAYNE, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in March.

• On Tuesday March 11, 2025, at 3:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Leerink Partners Global Healthcare Conference in Miami, Florida.
  
  
• On Thursday March 27, 2025, at 9:00 AM EDT, Dr. Walker and other members of Aclaris’ senior leadership team will participate in a virtual fireside chat during the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
  

A live and archived webcast of both events will be accessible on the Events page of https://www.aclaristx.com/. The webcasts will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
[email protected]

You May Also Be Interested In

• Vishay Intertechnology to Showcase Solutions for AI Infrastructure and Physical AI at PCIM Asia 2026
• Aulumu Redefines Urban Transit with Its New B01/B02 Urban Gear Sling Bags
• Cogent Communications Holdings Securities Fraud Class Action Result of Undisclosed Demand and Backlog Issues and approximately 29% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick